

RELIANCE

RELIA
NCE COMMERCIAL FINANCE LIMITED

4th Floor, D-Wing, Trade World, Kamala Mills Compound, S.B. Marg, Lower Parel Mumbai 400013
 Website: www.reliancemoney.co.in. E-mail: rcf.secretarial@relianceada.com
 CIN: U66010MH2000PLC128301

Extract of the Unaudited Financial Results for the Nine Months ended December 31, 2022
 [Regulation 52 (8), read with regulation 52 (4) of the Listing Regulations] (Rupees in crore)

Sr. No.	Particulars	Quarter ended		Year ended
		31-Dec-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Mar-22 (Audited)
1	Total Income from Operations	31.12	68.32	196.19
2	Net Profit / (Loss) for the period (before Exceptional and/or Extraordinary items)	(128.64)	(1,127.24)	(7,103.19)
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	2,009.88	(1,127.24)	(7,103.19)
4	Net Profit / (Loss) for the period after Tax (after Tax, Exceptional and/or Extraordinary items)	2,009.65	(1,127.24)	(7,079.30)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2,009.73	(1,127.23)	(7,079.09)
6	Paid-up Equity Share Capital	135.33	135.33	135.33
7	Reserves (excluding Revaluation Reserve)	(8,923.81)	(6,520.04)	(10,915.19)
8	Securities Premium Account	2,078.11	2,078.11	2,078.11
9	Net Worth	(8,388.48)	(5,984.71)	(10,379.86)
10	Paid-up Debt Capital / Outstanding Debt	6,758.93	9,831.56	9,832.72
11	Outstanding Redeemable Preference Shares	0.14	0.14	0.14
12	Debt Equity Ratio	(0.88)	(1.64)	(0.95)
13	Earnings Per Share (of Rs. 10/- each fully paid-up) ** Basic & Diluted (Rs.)	147.15	(83.30)	(523.13)
14	Capital Redemption Reserve	Not Applicable	Not Applicable	Not Applicable
15	Debenture Redemption Reserve	#	#	#
16	Debt Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable
17	Interest Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable

- Exceptional and/or Extraordinary items adjusted in the statement of Profit & Loss in accordance with Ind AS Rules/AS Rules, whichever is applicable.

Notes:
 a) The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchange(s) under Regulation 52 of the Listing Regulations. The full format of the quarterly financial results is available on the websites of the Stock Exchange(s) and the listed entity.
 b) For the other line items referred to in Regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on the website of the Stock Exchange i.e. www.bseindia.com.

c) The impact on net profit/loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.

** Not Annualised for Quarters

No DRR is required in respect of privately placed debentures in terms of Rule 18(7)(b)(i) of the Companies (Share Capital and Debentures) Rules, 2014.

For Reliance Commercial Finance Limited
 (Wholly owned Subsidiary of Aham Investment & Infrastructure Limited)

Sd/-
 Amit Dangi
 Director
 DIN: 06527044

Date: February 08, 2023

Place: Mumbai

CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT FOR ATTENTION TO THE SHAREHOLDERS OF PRISM MEDICO AND PHARMACY LIMITED (CIN: L24100HP2002PLC009299)
 ("PML" / "TARGET COMPANY" / "TC")

Registered Office: Suketi Road, Kala Amb, Sirmour, Himachal Pradesh-173 030, India Phone No. +91-172-5020759;
 Email id: investorgrvancewmcl@gmail.com; Website: www.prismmmedico.in

In compliance with Regulations 3 (1) and 4 read with Regulations 15 of the SEBI (SAST) Regulations, 2011. This corrigendum to the detailed public statement is being issued by Navigant Corporate Advisors Limited, on behalf of M/s. Symbiosis Pharmaceuticals Private Limited (Acquirer 1), M/s. Galaxy Vitacare Private Limited (Acquirer 2) and Mr. Ramit Walia (Acquirer 3) in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations") and the SEBI Observation Letter no. SEBI/HO/CDF/RAC/DR/2/P/OW/4759/1/2023 dated February 03, 2023 in respect of Open Offer ("Offer") for the acquisition up to 15,76,492 Equity Shares of Rs. 10/- each representing 26.00% of the total equity and voting share capital of the Target Company at a price of Rs. 11/- per share. The Detailed Public Statement ("DPS") pursuant to the Public Announcement ("PA") made by the Acquirers have appeared in Financial Express - English Daily (all editions); Jansatta - Hindi Daily (all editions); Pratkhak - Marathi Daily (Mumbai edition); Aapka Faista - Shimpla Edition covers Sirmour on December 05, 2022.

THE SHAREHOLDERS OF THE TARGET COMPANY ARE REQUESTED TO KINDLY NOTE THAT THE FOLLOWING INFORMATION RELATED TO OFFER:

1. Update in the schedule of Activities: The original and revised schedule of activities is set forth as below

Activity	Original Date	Original Day	Revised Date	Revised Day
Public Announcement	28.11.2022	Monday	28.11.2022	Monday
Publication of Detailed Public Statement in newspapers	05.12.2022	Monday	05.12.2022	Monday
Submission of Detailed Public Statement to BSE, MSEI, Target Company & SEBI	05.12.2022	Monday	05.12.2022	Monday
Last date of filing draft letter of offer with SEBI	12.12.2022	Monday	12.12.2022	Monday
Last date for a Competing offer	26.12.2022	Monday	26.12.2022	Monday
Receipt of comments from SEBI on draft letter of offer	02.01.2023	Monday	03.02.2023	Friday
Identified date	04.01.2023	Wednesday	07.02.2023	Tuesday
Date by which letter of offer be dispatched to the shareholders	11.01.2023	Wednesday	14.02.2023	Tuesday
Last date for revising the Offer Price	17.01.2023	Tuesday	20.02.2023	Monday
Comments from Committee of Independent Directors of Target Company	16.01.2023	Monday	17.02.2023	Friday
Advertisement of Schedule of activities for open offer, status of statutory and other approvals in newspapers and sending to SEBI, Stock Exchange and Target Company	17.01.2023	Tuesday	20.02.2023	Monday
Date of Opening of the Offer	18.01.2023	Wednesday	21.02.2023	Tuesday
Date of Closure of the Offer	01.02.2023	Wednesday	06.03.2023	Monday
Payment of consideration for the acquired shares	15.02.2023	Wednesday	21.03.2023	Tuesday
Final report from Merchant Banker	22.02.2023	Wednesday	29.03.2023	Wednesday

All other terms and conditions remain unchanged. Capitalized terms used in this announcement, but not defined, shall have the same meaning assigned to them in the PA, DPS and LOF.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

ISSUED BY MANAGER TO THE OFFER FOR AND ON BEHALF OF THE ACQUIRERS

M/S. SYMBIOSIS PHARMACEUTICALS PRIVATE LIMITED, M/S. GALAXY VITACARE PRIVATE LIMITED AND MR. RAMIT WALIA

Navigant Corporate Advisors Limited
 423, A Wing, Bonanza, Sahar Plaza Complex, B Nagar, Andheri Kurla Road, Andheri (East), Mumbai-400 059. Tel No. +91 22 4120 4837 / 4973 5078
 Email id: navigator@navigantcorp.com Website: www.navigantcorp.com
 SEBI Registration No: INM000012243 Contact person: Mr. Sarthak Viljani

Place: Mumbai Date: February 07, 2023

Sunjeet Comm.

